Core Viewpoint - The company has been enhancing its full value chain service capabilities and developing specialized platforms in niche areas, achieving significant results in new business sectors by the third quarter of 2025 [1] Group 1 - The company reported impressive performance in innovative drug services, import agency, health equipment, and CSO (Contract Sales Organization) businesses [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.02% on February 2, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Individual Stock Performance - The following stocks showed notable performance: - Huaren Health (301408) closed at 21.12, up 0.43% with a trading volume of 177,200 shares and a turnover of 379 million yuan [1] - Dazhenglin (603233) closed at 19.05, down 4.75% with a trading volume of 121,000 shares and a turnover of 235 million yuan [2] - Yifeng Pharmacy (603939) closed at 22.97, down 3.85% with a trading volume of 202,900 shares and a turnover of 472 million yuan [2] Capital Flow Analysis - The pharmaceutical commercial sector saw a net outflow of 208 million yuan from institutional investors, while retail investors had a net inflow of 166 million yuan [2] - The following stocks had significant capital flows: - Yifeng Pharmacy had a net inflow of 52.27 million yuan from institutional investors, but a net outflow of 61.65 million yuan from retail investors [3] - Nanjing Pharmaceutical (600713) had a net inflow of 7.79 million yuan from institutional investors, with a net outflow of 11.72 million yuan from retail investors [3]

Group 1 - The company, Liu Pharmaceutical Group (603368.SH), announced a share buyback program, with a total of 10.803 million shares repurchased as of January 31, 2026, representing 2.72% of the company's total share capital [1] - The highest price for the repurchased shares was 19.07 CNY per share, while the lowest price was 17.83 CNY per share [1] - The total amount paid for the repurchase, excluding transaction fees, was 199 million CNY [1]

发布时间：2026-02-02 行业投资评级 强于大市|维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 8338.3 | | 52 周最高 | 9323.49 | | 52 周最低 | 6876.88 | 行业相对指数表现 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 近期研究报告 2025 年有数十个 AI 衍生的管线进入人体临床试验，但回顾过往 管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲 折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验 水平的 1 期成功率（80%~90% vs 40%~65%），而在 2 期及后续的进 ...

Group 1 - The core viewpoint of the news is that Ruikang Pharmaceutical has experienced a decline in stock price and financial performance, with significant changes in financing and shareholder metrics [1][2]. - On January 30, Ruikang Pharmaceutical's stock fell by 1.76%, with a trading volume of 210 million yuan. The financing buy-in amount was 15.07 million yuan, while the financing repayment was 23.70 million yuan, resulting in a net financing outflow of 8.63 million yuan [1]. - As of January 30, the total balance of margin trading for Ruikang Pharmaceutical was 244 million yuan, which accounts for 4.85% of its circulating market value, indicating a high level compared to the past year [1]. - The company has a significant margin balance, with a margin repayment of 5,700 shares and a margin sell-out of 5,200 shares on January 30, with a margin balance of 444,200 yuan, also at a high level compared to the past year [1]. - Ruikang Pharmaceutical's main business includes direct sales of pharmaceuticals (80.73% of revenue), medical devices (17.70%), mobile healthcare (0.67%), and other services [1]. Group 2 - As of October 31, the number of shareholders for Ruikang Pharmaceutical was 72,300, a decrease of 0.82% from the previous period, while the average circulating shares per person increased by 0.83% to 18,879 shares [2]. - For the period from January to September 2025, Ruikang Pharmaceutical reported a revenue of 5.407 billion yuan, a year-on-year decrease of 10.73%, and a net profit attributable to shareholders of 12.14 million yuan, down 68.73% year-on-year [2]. - Since its A-share listing, Ruikang Pharmaceutical has distributed a total of 393 million yuan in dividends, with 36.03 million yuan distributed over the past three years [3].

Core Viewpoint - Seer Medical (603716) has experienced a significant decline in stock price, closing at 22.12 yuan, down 12.47% from the previous week, with a current market capitalization of 4.65 billion yuan [1] Group 1: Trading Information - On January 28, Seer Medical executed a block trade with a transaction amount of 22 million yuan [2] Group 2: Shareholder Changes - Shareholder Shanghai Angze Private Fund Management Co., Ltd. reduced its holdings by 1.5 million shares from December 12, 2025, to January 28, 2026, representing 0.7137% of the total share capital. The total reduction amounted to 3,091,200 shares, or 1.47% of the total share capital, with a remaining holding of 4.29% [3][5] Group 3: Performance Disclosure - Seer Medical anticipates a net loss attributable to shareholders for the year 2025 ranging from 160 million yuan to 209 million yuan, with a net loss excluding non-recurring gains and losses expected between 180 million yuan and 230 million yuan. The anticipated loss is primarily due to a decline in operating income, increased R&D expenses, and impairment of credit and goodwill [4][5][7]

在融入中国光大集团体系八年后，央企旗下的医药商业上市公司嘉事堂（002462.SZ）可能即将迎 来又一次重大的所有权变革。 根据嘉事堂发布的《关于筹划控制权变更事项的停牌公告》，公司于2026年1月27日接到股东中国 光大实业（集团）有限责任公司（以下简称"光大实业"）的书面通知。光大实业及其全资子公司中国光 大医疗健康产业有限公司（以下简称"光大医疗"）正在筹划公司的股权转让事宜。该事项可能导致嘉事 堂的控股股东、实际控制人发生变更。 鉴于交易尚存在重大不确定性，为保障公平信息披露，经向深圳证券交易所申请，公司股票自2026 年1月28日（星期三）开市起停牌，预计停牌时间不超过2个交易日。公司表示，停牌期间将根据事项进 展履行信披义务，待确定后将及时公告并申请复牌。 公开资料显示，截至2025年第三季度末，光大医疗、光大实业分别为嘉事堂的第一、第二大股东， 直接持股比例分别为14.36%和14.12%。 据悉，嘉事堂于2010年在深交所上市，2018年进入光大集团体系，被定位为集团在大健康业务板块 的主要平台之一。其主营业务聚焦于医药商业流通领域，目前已构建了覆盖医药批发、零售、物流及医 疗器械供应链的完整 ...

Core Viewpoint - The pharmaceutical company Jiasitang (002462.SZ), under the China Everbright Group for eight years, is undergoing a significant ownership change due to a planned share transfer by its major shareholders, which may lead to a change in the controlling shareholder and actual controller [2][5]. Group 1: Ownership Change - Jiasitang announced a stock suspension starting January 28, 2026, due to the uncertainty surrounding the potential change in control [2][5]. - The major shareholders, China Everbright Industrial Group and its subsidiary China Everbright Medical Health Industry, hold 14.36% and 14.12% of Jiasitang's shares, respectively [6]. Group 2: Business Overview - Jiasitang focuses on pharmaceutical distribution, with over 94% of its total revenue coming from pharmaceutical wholesale as of the end of 2024 [7]. - The company operates a chain of "Jiasitang" pharmacies, with over 200 directly operated stores in Beijing, previously being one of the largest direct pharmacy operators in the region [8]. Group 3: Financial Performance - Jiasitang's net profit has been declining for three consecutive years, with figures of 297 million yuan, 250 million yuan, and 161 million yuan from 2022 to 2024, marking a significant drop of 35.75% in 2024 [11]. - In the first three quarters of 2025, the net profit further decreased by 38.81% year-on-year, amounting to 141 million yuan [12]. - The company's gross margin has fallen from over 10% to 6.59% in 2023, with a slight recovery to 6.61% in 2024, but dropping again to 6.28% in the first three quarters of 2025 [14]. - Revenue has also contracted, with 2024 revenue at 24.02 billion yuan, down approximately 20%, and 2025 revenue for the first three quarters at 14.46 billion yuan, down 21.80% [15].

1. Reported Industry Investment Rating - No information provided in the given content 2. Core Viewpoints of the Report - The company's 2026 Employee Stock Ownership Plan (Draft) shows management's confidence in future development and the core team's optimism about the market prospects of core business products [26]. - The company has set three - year (2026 - 2028) performance assessment targets for the employee stock ownership plan, aiming to achieve revenue of 1 billion yuan in 2026, 1.5 billion yuan in 2027, and 2 billion yuan in 2028, and考核利润 of 300 million yuan in 2026, 500 million yuan in 2027, and 800 million yuan in 2028 [26]. - With the approval of multiple core products, the company's existing business revenue is expected to grow significantly in 2026, and there will be explosive growth in 2027 and 2028 [28]. 3. Summary by Relevant Catalogs 3.1 Research Basic Situation - Research object: Taienkang [16] - Industry: Pharmaceutical commerce [16] - Reception time: January 29, 2026 [16] - Listed company reception personnel: Li Ting, Director, Deputy General Manager, and Secretary of the Board of Directors [16] 3.2 Detailed Research Institutions - Securities companies: Huatai Securities, China Merchants Securities, Ping An Securities, Zhongtai Securities, Founder Securities, Huachuang Securities, Cinda Securities, CITIC Securities Co., Ltd., Tianfeng Securities, Shenwan Hongyuan, Guotai Haitong, Industrial Securities, Guohai Securities, Huafu Securities, Huaxi Securities, Galaxy Securities [17][18][20] - Fund management companies: Dacheng, Huabao, Huian, Huatai - PineBridge Fund, China Asset Management, Galaxy, Jianxin, Hangzhou Youyizeng Private Equity, Puyin AXA, Anxin, Hehe (Beijing) Private Equity, Morgan Stanley Fund Management (China), Hainan Ling Private Equity, Guoshou Anbao [17][18][19] - Asset management companies: Yong'an Guofu, Shanghai Yuxiu, Guangdong Hongyi, Huafu Securities, Zhongyin International Securities Co., Ltd. Asset Management, Ping An Insurance Asset Management, Fushun Asset Management (Shanghai), Zhonghuili Asset Management, Shanghai Qingding, Beijing Hanhe and Hanhua [18][19][20] - Investment companies: Shanghai Hengfu, Shanghai Zige, Zhejiang Yiheng, Beijing Zhuoyu, Shanghai Guanche [18][19] - Others: Western Medicine, Dongfang Investment Consulting, Dongcai Medicine, Hwa Site Asset Management, Northeast Medicine, Dongfang Medicine, Xiangwang Fund [18][19][20] 3.3 Research Institution Proportion - No information provided in the given content 3.4 Main Content Data - **Employee Stock Ownership Plan** - Fund - raising: The total amount of funds to be raised is 33.608 million yuan, with no more than 145 participants including directors, senior managers, and core employees, and all funds come from employees' legal salaries and self - raised funds [26]. - Assessment targets: From 2026 - 2028, the assessment indicators are revenue and考核利润 (deducted non - recurring profit and loss attributable to the parent + R & D expenses - investment income from associated and joint - venture enterprises - share - based payment expenses) [26]. - Incentive form: Employee stock ownership plan, employees need to contribute funds first and obtain shares through non - trading transfer [26]. - Unlock ratio: Unlock in three phases from 2026 - 2028, with 40%, 40%, and 20% respectively [28]. - Incentive shares: Approximately 1.98 million shares, sourced from the company's previous share repurchases [28]. - **Revenue and Profit Targets** - The company's existing products such as "Aitingjiu" for sexual health, "Wolitin" for ophthalmology, and Chinese patent medicines will maintain stable income [28]. - Multiple core products will be approved or applied for, including "Aitinglie" non - finasteride - tadalafil compound capsule (domestic first imitation) approved in December 2025, lidocaine - prilocaine aerosol (domestic first imitation) expected to be accepted by the drug administration soon, compound sodium sulfate tablets (domestic first imitation) expected to be approved in the first half of 2026, Heweizhengchang Pills (domestic exclusive) for localized production registration expected to be approved in the first half of 2026, and pilocarpine hydrochloride eye drops for presbyopia (domestic first imitation) expected to be approved in the second half of 2026 [28]. - **Heweizhengchang Pills Localized Production** - Since the second half of 2025, the company has carried out brand promotion in traditional advantageous regions such as Guangdong, Guangxi, and Fujian through platforms like Focus Media, Xiaohongshu, and Douyin [28]. - Actively expand third - party terminal channels such as clinics and Internet hospitals, and increase investment in online platforms such as Douyin, JD, and Tmall. Sales on the Douyin platform have increased significantly in January [28]. - After the domestic localization of Heweizhengchang Pills, multiple product specifications will be added to meet different needs and maintain the price system, with good sales expected in the first and second quarters of this year [28]. - **CKBA for Alzheimer's Disease** - Developed from AKBA, a natural triterpenoid compound from frankincense, CKBA can specifically target MFE - 2, a key metabolic enzyme in the peroxisomal β - oxidation pathway, maintaining lipid metabolism homeostasis in microglia and inhibiting the release of pro - inflammatory factors [28][29]. - Animal experiments show that oral CKBA can cross the blood - brain barrier, has no obvious toxic side effects, and has multiple therapeutic effects in Alzheimer's disease model mice [29]. - **Commercialization Preparation for New Products** - Increase brand promotion investment, cooperate with Meituan in addition to existing channels, and the sales on online platforms such as Meituan, Tmall, JD, and Douyin are increasing [29]. - Establish a specialized third - party terminal team to develop clinic and Internet hospital channels and adjust the sales team [29]. - For specific products, promote the inclusion of compound sodium sulfate tablets in medical insurance after approval; start medical insurance - related work for non - finasteride - tadalafil compound capsules, and continue in - depth brand promotion [30]. - **Progress of Child Vitiligo and Rosacea** - Rosacea may progress faster and is expected to be the first indication for CKBA to submit a registration application. The company aims to complete Phase III clinical trials by the end of 2027 [30]. - Child vitiligo Phase II clinical trials aim to enroll the first patient in March - April 2026 and basically complete Phase II clinical trials in the first half of 2027 [31]. - **Overseas Market of Child Vitiligo** - The company focuses on the domestic registration and listing of child vitiligo in 2 - 12 - year - old children. There is currently no approved product globally, and the company plans to start the IND application for the US FDA this year [32].

Core Viewpoint - The company 嘉事堂 announced a potential change in its controlling shareholder and actual controller due to a planned equity transfer by its shareholder 光大实业, leading to a suspension of its stock trading [1] Group 1: Company Announcement - 嘉事堂 received a written notice from its shareholder 光大实业 regarding the planning of an equity transfer, which may result in a change of the company's controlling shareholder and actual controller [1] - The company has applied for a trading suspension starting from January 28, as the transaction is still in progress and no formal agreement has been signed yet [1] - Due to the uncertainty surrounding the transaction, 嘉事堂 has applied for an extension of the trading suspension, which is expected to last no more than three trading days [1]